CEO of Pfizer says third vaccine dose is needed within 6 to 12 months

A staff member of the National Health Service is set to administer the Oxford / Astragena Kovid-19 vaccine in London on 21 March.

Researchers at Oxford University have found that the risk of a rare type of blood clotting is lower overall, but that those infected with Kovid-19 are higher than those who have three authorized vaccines in the UK – Modern and Pfizer, made by AstraAnica.

The study, made available in pre-print on the Oxford website on Thursday before publication in the Scientific Journal, states that the risk of cerebral venous thrombosis or CVT – also known as cerebral venous sinus thrombosis or CVST – of Covid-19 infection The latter is “100 times higher than normal in all age groups and many times more after vaccination or influenza”.

“Kovid-19 markedly increases the risk of CVT, leading to increased blood clotting problems,” said Paul Harrison, professor of psychiatry at the University of Oxford and head of the neurobiology group.

Oxford University, which developed the AstraZeneca vaccine, said the research is from a different part of the university and is not linked to the vaccine team. The data used was obtained from external sources, most notably the European Medical Agency.

When compared to the risk of clots from three vaccines, the risk of infection is “8–10 times greater and about 100 times higher than baseline,” Oxford said in a news release. According to research, when compared with mRNA vaccines – Pfizer and Moderna – the risk of CVT from covid-19 infection is approximately 10 times higher. When compared with AstraZeneca, the risk of CVT from Kovid-19 is approximately eight times higher. The Johnson & Johnson Kovid-19 vaccine was not included in the analysis.

Using an electronic health record network of more than 500,000 Kovid-19 positive cases, 489,871 vaccination cases and more than 172,724 cases of influenza, the study found that 30% of CVT cases occurred in the under-aged age group, The highest risk for blood clots.

“Even for people under 30, the balance between risk and COVID-19 risk with current vaccines is high; When considering the balance between the risks and benefits of vaccination, a few things should be noted.

Dr. of Oxford’s Translational Neurobiology Group. Maxim Taquet and study co-authors cautioned that the data was still accruing. Researchers have also determined that Covid-19 and vaccines proceed in the same way for CVT, he said.

Experts noted that CVT is so rare, there is limited data even before the epidemic, and data and data sources around the Kovid-19 vaccine are inconsistent and limited.

“The main finding overall is that these CVT events are very rare – some out of every one million people involved – in Kovid-19 patients, and among those who had one of the vaccines – but they are very rare among those with the vaccine. Were rare. Compared to the Kovid-19 ones, “Kevin McConvey, in a comment to the Science Media Center in the UK at the Open University, emerged professor of applied statistics. “Researchers are not claiming that vaccines do not increase the risk at all compared to the risk in people who have not been vaccinated and do not even have Kovid-19 – but they say there is a CVT risk in those people Which is Kovid-19, almost 100 times the risk in the general population. “

Some background: European and British drug regulators made an announcement last week “Possible link“Amidst rare cases of AstraZeneca vaccine and blood clots, the UK announced that it would offer alternative vaccines to people under 30. Other countries have followed suit and either offered only to those above a certain age. Doing or, like Denmark and Norway, completely scraping the vaccine. Advising the public to look for signs of clotting, regulators said the benefits of the shot were still worth the risk. The AstraZeneca vaccine was given the United States. Has not been authorized for use in.

Six reports of similar clotting events after vaccination with the single dose Johnson & Johnson vaccine Inspired by the US Center for Disease Control and Prevention and the US Food and Drug Administration To recommend a pause to allow the vaccine for further investigation.

Six women between the ages of 18 and 48 had developed venous sinus thrombosis of the brain, a clot in the area of ​​the brain that destroys blood and collects blood. Blood thinners, specific treatments for clots, should not be used in such cases. The six reported cases were between more than 6.8 million doses of the Johnson & Johnson vaccine administered in the United States.

The European Union, which relies too heavily on the J&J vaccine to increase its lagging vaccination rollout, has also stopped using the shot. The European Medical Agency is expected to decide on the administration of the Johnson & Johnson vaccine next week.

The WHO said on Thursday “Now the risk of suffering blood clots is much higher for someone with COVID-19 who has taken the AstraZeneca vaccine.” WHO Europe’s Regional Director Hans Kluge reiterated his recommendation of the AstraZeneca vaccine for all eligible adults, calling it “effective in preventing COVID-19 hospitalization and deaths”.


Source link

Popular Topics

Related Articles